Bio-Rad Laboratories and Axis-Shield have launched Bio-Rad’s BioPlex 2200 Anti-CCP test for the early detection of rheumatoid arthritis. The assay, which will run on Bio-Rad’s BioPlex 2200 system, measures anti-CCP (anti-cyclic citrullinated peptide antibodies), a marker that has been shown to have superior specificity in the diagnosis of rheumatoid arthritis.

The BioPlex 2200 Anti-CCP kit is based on Axis-Shield’s proprietary anti-CCP technology. The assay is available for sale in certain countries outside the US. It is a fully automated, random-access multiplex testing platform with an assay menu targeting autoimmune diagnostics and infectious diseases. In the US, the BioPlex 2200 Anti-CCP kit is pending clearance by the FDA.

John Goetz, vice president and group manager of Clinical Diagnostics at Bio-Rad, said: “The anti-CCP testing market is one of the fastest growing markets in autoimmune diagnostics. The addition of this assay will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system.”

Ian Gilham, CEO of Axis-Shield, said: “We are very pleased that Bio-Rad has reached this important commercial milestone in our agreement and believe that availability on the BioPlex system will help expand the market for this important early marker for this debilitating condition.

“The measurement of these antibodies has recently been cited as a key parameter in the definitive diagnosis of rheumatoid arthritis by the influential American College of Rheumatology.”